var data={"title":"Oxaliplatin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxaliplatin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6692?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxaliplatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxaliplatin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=oxaliplatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxaliplatin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709183\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity/Anaphylactic reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic reactions to oxaliplatin have been reported and may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of anaphylaxis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204261\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Eloxatin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6821523\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eloxatin;</li>\n      <li>Oxaliplatin Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204285\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Alkylating Agent;</li>\n      <li>\n        Antineoplastic Agent, Platinum Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204263\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Oxaliplatin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer (advanced):</b> IV: 85 mg/m<sup>2</sup> every 2 weeks until disease progression or unacceptable toxicity (in combination with infusional fluorouracil/leucovorin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colon cancer, stage III (adjuvant therapy):</b> IV: 85 mg/m<sup>2</sup> every 2 weeks (in combination with infusional fluorouracil/leucovorin) for 6 months (12 cycles; in combination with infusional fluorouracil/leucovorin). A pooled analysis of 6 phase III studies suggests that a 3-month adjuvant oxaliplatin-based treatment duration is not inferior to 6 months of adjuvant oxaliplatin-based treatment in properly-selected subgroups of patients with stage III colon cancer (Shi 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colon/colorectal cancer (off-label doses or combinations):</b> IV: 85 mg/m<sup>2</sup>/dose on days 1, 15, and 29 of an 8-week treatment cycle in combination with fluorouracil/leucovorin (Kuebler 2007) <b>or</b> 85 mg/m<sup>2</sup> every 2 weeks in combination with fluorouracil/leucovorin/irinotecan (Falcone 2007) <b>or</b> 130 mg/m<sup>2</sup> every 3 weeks in combination with capecitabine (Cassidy 2008; Haller 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Biliary adenocarcinoma, advanced (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GEMOX regimen: 100 mg/m<sup>2</sup> on day 2 every 2 weeks (in combination with gemcitabine) until disease progression or unacceptable toxicity (Andre 2004) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CAPOX regimen: 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) until disease progression or unacceptable toxicity (Nehls 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia, fludarabine-refractory (off-label use):</b> IV: OFAR regimen: 25 mg/m<sup>2</sup>/day for 4 days every 4 weeks (in combination with fludarabine, cytarabine, and rituximab) for up to 6 cycles (Tsimberidou 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal/gastric cancers (off-label use):</b> IV: 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with epirubicin and either capecitabine or fluorouracil) for up to 8 cycles (Cunningham 2008) <b>or</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with docetaxel, leucovorin, and fluorouracil) for up to 8 cycles (Al-Batran 2008) <b>or</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with leucovorin and fluorouracil; FOLFOX4) for 6 cycles (Conroy 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gastric cancer:</i> IV: 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) for 8 cycles (Bang 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuroendocrine tumors (carcinoid), refractory (off-label use):</b> IV: 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) for up to 6 cycles (Bajetta 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-Hodgkin lymphoma, relapsed/refractory (off-label use):</b> IV: 100 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with gemcitabine and rituximab) (Lopez 2008; Rodriguez 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer, advanced (off-label use):</b> IV: 130 mg/m<sup>2</sup> once every 3 weeks until disease progression or unacceptable toxicity (Dieras 2002; Piccart 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic cancer, advanced (off-label use):</b> IV: 85 mg/m<sup>2</sup> every 2 weeks (in combination with fluorouracil, leucovorin, and irinotecan; FOLFIRINOX regimen) for up to 6 months (Conroy 2011) <b>or</b> 110 to 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) until disease progression or unacceptable toxicity (Xiong 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Testicular cancer, refractory (off-label use):</b> IV: 130 mg/m<sup>2</sup> every 3 weeks in combination with gemcitabine (De Georgi 2006; Kollmannsberger 2004; Pectasides 2004) <b>or</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with gemcitabine and paclitaxel) for up to 8 cycles (Bokemeyer 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Unknown primary cancer, recurrent or refractory (off-label use):</b> IV: 130 mg/m<sup>2</sup> on day 1 of a 21-day cycle (in combination with capecitabine) for 6 cycles or may continue until clinical benefit no longer realized (Hainsworth 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50906907\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=oxaliplatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Oxaliplatin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Neuroblastoma, high-risk, relapsed/refractory (off-label use): </b>Children and Adolescents: IV: 105 mg/m<sup>2</sup> on day 1 (in combination with doxorubicin, dexrazoxane, and myeloid growth factors) every 21 days (Mascarenhas 2013; Tran 2015). Additional studies are necessary to further define the role of oxaliplatin in this condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204264\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204265\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer's labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Reduce dose from 85 mg/m<sup>2</sup> to 65 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alternate recommendations:</b> CrCl &ge;20 mL/minute: In a study with a limited number of patients with mild to moderate impairment, defined by the authors as CrCl 20 to 59 mL/minute (determined using 24-hour urine collection), oxaliplatin was well tolerated, suggesting a dose reduction may not be necessary in patients with CrCl &ge;20 mL/minute receiving every-3-week dosing (dose range: 80 to 130 mg/m<sup>2</sup> every 3 weeks) (Takimoto 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6821524\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Mild, moderate, or severe impairment: No dosage adjustment necessary (Doroshow 2003; Synold 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20342799\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204286\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Acute toxicities:</b> Longer infusion time (6 hours) may mitigate acute toxicities (eg, pharyngolaryngeal dysesthesia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neurosensory events:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent (&gt;7 days) grade 2 neurosensory events:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjuvant treatment of stage III colon cancer: Reduce dose to 75 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Advanced colorectal cancer: Reduce dose to 65 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Consider withholding oxaliplatin for grade 2 neuropathy lasting &gt;7 days despite dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent (&gt;7 days) grade 3 neurosensory events: Consider discontinuing oxaliplatin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal toxicity (grade 3/4) occurring despite prophylactic treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjuvant treatment of stage III colon cancer: Delay next dose until recovery from toxicity, then reduce dose to 75 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advanced colorectal cancer: Delay next dose until recovery from toxicity, then reduce dose to 65 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematologic toxicity (grade 4 neutropenia [Canadian labeling: grade 3 or 4 neutropenia], febrile neutropenia, or grade 3/4 thrombocytopenia):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjuvant treatment of stage III colon cancer: Delay next dose until neutrophils recover to &ge;1500/mm<sup>3</sup> and platelets recover to &ge;75,000/mm<sup>3</sup>, then reduce dose to 75 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advanced colorectal cancer: Delay next dose until neutrophils recover to &ge;1500/mm<sup>3</sup> and platelets recover to &ge;75,000/mm<sup>3</sup>, then reduce dose to 65 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pulmonary toxicity (unexplained respiratory symptoms including nonproductive cough, dyspnea, crackles, pulmonary infiltrates):</b> Discontinue until interstitial lung disease or pulmonary fibrosis have been excluded.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rhabdomyolysis:</b> Discontinue for signs/symptoms of rhabdomyolysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sepsis or septic shock:</b> Withhold treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204242\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eloxatin: 50 mg/10 mL (10 mL [DSC]); 100 mg/20 mL (20 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/10 mL (10 mL); 100 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204229\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204244\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as IV infusion over 2 hours; extend infusion time to 6 hours for acute toxicities. Flush infusion line with D<sub>5</sub>W prior to administration of any concomitant medication. Avoid mucositis prophylaxis with ice chips, exposure to cold temperatures, or consumption of cold food/beverages during or within hours after oxaliplatin infusion (may exacerbate acute neurological symptoms). Do not use needles or administration sets containing aluminum. When used in combination with a fluoropyrimidine (eg, 5-FU), infuse oxaliplatin first.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oxaliplatin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; monitor IV site for redness, swelling, or pain.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Information conflicts regarding use of warm or cold compresses. Cold compresses may cause local vasoconstriction and reduce cellular injury; however, may cause or exacerbate peripheral neuropathy; warm compresses may increase local drug removal, although may also increase cellular uptake and injury (de Lemos 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132766\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204243\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colon cancer, stage III (adjuvant therapy):</b> Adjuvant treatment of stage III colon cancer (in combination with infusional fluorouracil and leucovorin) after complete resection of primary tumor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer, advanced:</b> Treatment of advanced colorectal cancer (in combination with infusional fluorouracil and leucovorin).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469518\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Biliary adenocarcinoma, advanced; Chronic lymphocytic leukemia, refractory; Esophageal cancer; Gastric cancer; Neuroblastoma, high-risk, relapsed/refractory (pediatrics); Neuroendocrine tumors (carcinoid), refractory; Non Hodgkin lymphoma, relapsed/refractory; Ovarian cancer, advanced; Pancreatic cancer, advanced or metastatic; Testicular cancer, refractory; Unknown primary cancer, recurrent or refractory</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204295\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oxaliplatin may be confused with Aloxi, carboplatin, cisplatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204234\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentages reported with monotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Peripheral neuropathy (may be dose limiting; 76% to 92%; acute 65%; grades 3/4: 5%; persistent 43%; grades 3/4: 3%), fatigue (61%), pain (14%), headache (13%), insomnia (11%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (64%), diarrhea (46%), vomiting (37%), abdominal pain (31%), constipation (31%), anorexia (20%), stomatitis (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (64%; grades 3/4: 1%), thrombocytopenia (30%; grades 3/4: 3%), leukopenia (13%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum AST (54%; grades 3/4: 4%), increased serum ALT (36%; grades 3/4: 1%), increased serum bilirubin (13%; grades 3/4: 5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (11%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (13%), cough (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (10%), chest pain (5%), peripheral edema (5%), flushing (3%), thromboembolism (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Rigors (9%), dizziness (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (5%), alopecia (3%), palmar-plantar erythrodysesthesia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Dehydration (5%), hypokalemia (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (7%), dysgeusia (5%), flatulence (3%), hiccups (2%), mucositis (2%), dysphagia (acute 1% to 2%), gastroesophageal reflux disease (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Dysuria (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (3%; includes urticaria, pruritus, facial flushing, shortness of breath, bronchospasm, diaphoresis, hypotension, syncope: grades 3/4: 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (9%; redness, swelling, pain) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (7%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocular: Abnormal lacrimation (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (5% to 10%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory tract infection (7%), rhinitis (6%), epistaxis (2%), pharyngitis (2%), pharyngolaryngeal dysesthesia (grades 3/4: 1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (reported with mono- and combination therapy): Abnormal gait, acute renal failure, anaphylaxis, anaphylactic shock, anaphylactoid reaction, angioedema, aphonia, ataxia, blepharoptosis, cerebral hemorrhage, colitis, cranial nerve palsy, decreased deep tendon reflex, deafness, decreased visual acuity, diplopia, dysarthria, eosinophilic pneumonitis, fasciculations, febrile neutropenia, hematuria, hemolysis, hemolytic anemia (immuno-allergic), hemolytic-uremic syndrome, hemorrhage, hepatic failure, hepatic fibrosis (perisinusoidal), hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease), hepatitis, hepatotoxicity, hypertension, hypomagnesemia, hypoxia, idiopathic noncirrhotic portal hypertension (nodular regenerative hyperplasia), increased INR, increased serum alkaline phosphatase, infusion related reaction (extravasation [including necrosis]), interstitial nephritis (acute), interstitial pulmonary disease, intestinal obstruction, laryngospasm, Lhermittes' sign, metabolic acidosis, muscle spasm, myoclonus, neutropenic enterocolitis, neutropenic infection (sepsis), optic neuritis, pancreatitis, prolonged Q-T interval on ECG, prolonged prothrombin time, pulmonary fibrosis, purpura, rectal hemorrhage, renal tubular necrosis, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, seizure, sepsis, septic shock, temporary vision loss, thrombocytopenia (immuno-allergic), torsades de pointes, trigeminal neuralgia, ventricular arrhythmia, visual field loss, voice disorder </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204247\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to oxaliplatin, other platinum-containing compounds, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pregnancy, breast-feeding; severe renal impairment (CrCl &lt;30 mL/minute)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204232\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Grade 3 and 4 neutropenia occurs commonly with oxaliplatin in combination with fluorouracil and leucovorin; sepsis, neutropenic sepsis, and septic shock have been reported with oxaliplatin (some fatal). Delay oxaliplatin treatment until neutrophils are &ge;1500/mm<sup>3</sup>; withhold treatment for sepsis or septic shock. Reduce the dose after recovery from grade 4 neutropenia or neutropenic fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiotoxicity: QT prolongation and ventricular arrhythmias, including fatal torsades de pointes have been reported in postmarketing surveillance. ECG monitoring is recommend in patients with heart failure, bradyarrhythmias, concomitant medications known to cause QT prolongation (including class Ia and III antiarrhythmics), and electrolyte abnormalities. Avoid use in patients with congenital long QT syndrome. Monitor potassium and magnesium prior to and periodically during treatment; correct hypokalemia and hypomagnesemia prior to treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Oxaliplatin is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Oxaliplatin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016). Fluorouracil and leucovorin are associated with GI adverse events; the incidence of GI toxicity is increased when oxaliplatin is administered with fluorouracil and leucovorin. Mucositis, stomatitis, GI bleeding, and GI obstruction have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Anaphylactic reactions have been reported with oxaliplatin (may occur within minutes of administration); symptoms may be managed with epinephrine, corticosteroids, antihistamines, </b> and discontinuation; oxygen and bronchodilators have also been used (Kim 2009). Grade 3 or 4 hypersensitivity has been observed. Allergic reactions are similar to reactions reported with other platinum analogs and may occur with any cycle. Reactions typically occur after multiple cycles; in retrospective reviews, reaction occurred at a median of 7 to 9 cycles, with an onset of 5 to 70 minutes (Kim 2009; Polyzos 2009). Symptoms may include bronchospasm (rare), erythema, hypotension (rare), pruritus, rash, and/or urticaria; previously-untreated patients have also experienced flushing, diaphoresis, diarrhea, shortness of breath, chest pain, hypotension, syncope, and disorientation. According to the manufacturer, rechallenge is contraindicated (deaths due to anaphylaxis have been associated with platinum derivatives). In patients rechallenged after mild hypersensitivity, reaction recurred at a higher level of severity; for patients with severe hypersensitivity, rechallenge (with 2 to 3 days of antihistamine and corticosteroid premedication, and prolongation of infusion time) allowed for 2 to 4 additional oxaliplatin cycles; however, rechallenge was not feasible in nearly two-thirds of patients due to the severity of the initial reaction (Polyzos 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity (including rare cases of hepatitis and hepatic failure) has been reported. Liver biopsy has revealed peliosis, idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia), sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions. The presence of hepatic vascular disorders (including veno-occlusive disease) should be considered, especially in individuals developing portal hypertension or who present with increased liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Two different types of peripheral sensory neuropathy may occur: The first type of neuropathy is an acute presentation (within hours to 1 to 2 days), reversible (resolves within 14 days), with primarily peripheral symptoms that are often exacerbated by cold (may include pharyngolaryngeal dysesthesia); avoid mucositis prophylaxis with ice chips, exposure to cold temperatures, or consumption of cold food/beverages during or within hours after oxaliplatin infusion (may exacerbate symptoms); this acute neuropathy commonly recurs with subsequent doses. Cold-triggered neuropathy may last up to 7 days after oxaliplatin administration (Grothey 2011). The second type of neuropathy is a more persistent (&gt;14 days) presentation that often interferes with daily activities (eg, writing, buttoning, swallowing); these symptoms may improve in some patients upon discontinuing treatment. In a retrospective evaluation of patients treated with oxaliplatin for colorectal cancer, the incidence of peripheral sensory neuropathy was similar between diabetic and nondiabetic patients (Ramanathan 2010). Several retrospective studies (as well as a small, underpowered randomized trial) have suggested calcium and magnesium infusions before and after oxaliplatin administration may reduce incidence of cumulative sensory neuropathy; however, a recent abstract of an ongoing randomized, placebo-controlled, double-blind study in patients with colorectal cancer suggests there is no benefit of calcium and magnesium in preventing sensory neuropathy or in decreasing oxaliplatin discontinuation rates (Loprinzi 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: May cause pulmonary fibrosis (may be fatal); withhold treatment for unexplained pulmonary symptoms (eg, crackles, dyspnea, nonproductive cough, pulmonary infiltrates) until interstitial lung disease or pulmonary fibrosis are excluded.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reversible posterior leukoencephalopathy syndrome: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) have been reported. Signs/symptoms include headache, mental status changes, seizure, blurred vision, blindness and/or other vision changes; may be associated with hypertension. Diagnosis is confirmed with brain imaging.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rhabdomyolysis: Rhabdomyolysis (including fatal cases) has been reported with oxaliplatin. Discontinue if signs/symptoms of rhabdomyolysis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; increased toxicity may occur. Reduce initial dose in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients are more sensitive to adverse events, particularly diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Oxaliplatin is for IV administration. Administration via the intraperitoneal route (not an approved administration route) is associated with peritoneal hemorrhage and hemorrhagic complications (Charrier 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299798\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204236\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10180&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Platinum Derivatives may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204238\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204249\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies at one-tenth the equivalent human dose. Women of childbearing potential should be advised to avoid pregnancy and use effective contraception during treatment. Males and females of reproductive potential desiring children should consider fertility preservation prior to therapy (Levi 2015; O'Neil 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3017308\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if oxaliplatin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue breast-feeding or to discontinue oxaliplatin taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204240\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, blood chemistries, including serum creatinine, ALT, AST, and bilirubin (prior to each cycle), electrolytes, including potassium and magnesium (prior to and periodically during treatment); INR and prothrombin time (in patients on oral anticoagulant therapy); neurologic evaluation prior to each dose and periodically thereafter; hypersensitivity; respiratory effects; RPLS </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204231\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oxaliplatin, a platinum derivative, is an alkylating agent. Following intracellular hydrolysis, the platinum compound binds to DNA forming cross-links which inhibit DNA replication and transcription, resulting in cell death. Cytotoxicity is cell-cycle nonspecific.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204246\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 440 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;90% primarily albumin and gamma globulin (irreversible binding to platinum) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nonenzymatic (rapid and extensive), forms active and inactive derivatives</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Oxaliplatin ultrafilterable platinum (terminal): Median: 293 hours; range: 187 to 662 hours (Beaty 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Oxaliplatin ultrafilterable platinum: Distribution: Alpha phase: 0.4 hours; Beta phase: 16.8 hours; Terminal: 391 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~54%); feces (~2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323568\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oxaliplatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/10 mL (10 mL): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/20 mL (20 mL): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Oxaliplatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $240.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539908\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ai Heng (CN);</li>\n      <li>Crisapla (UY);</li>\n      <li>Dacotin (IN);</li>\n      <li>Dacplat (AR);</li>\n      <li>Eloxatin (AE, AT, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, GB, GT, HK, HN, HR, ID, IE, IL, IT, JO, KR, KW, LU, MT, MX, MY, NI, NL, NZ, PA, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SV, TH, TR, TW, VN);</li>\n      <li>Eloxatine (FR, LB, RU, VE);</li>\n      <li>Elplat (JP);</li>\n      <li>Entia (TH);</li>\n      <li>Henplatin (PH);</li>\n      <li>Kebir (PY);</li>\n      <li>Liplatin (KR);</li>\n      <li>Loxatron (LK);</li>\n      <li>Lyoxatin (VN);</li>\n      <li>Meslatin (PH);</li>\n      <li>Olatin (TW);</li>\n      <li>Olipcis (MX);</li>\n      <li>Oplat (CO);</li>\n      <li>Oxalatin (AU);</li>\n      <li>Oxalee (PH);</li>\n      <li>Oxalem (PH);</li>\n      <li>Oxalip (TH, TW);</li>\n      <li>Oxalitin (KR);</li>\n      <li>Oxalotin (BD);</li>\n      <li>Oxaltic (AR);</li>\n      <li>Oxaltie (EC, LB, LK, PK);</li>\n      <li>Oxapla (KR);</li>\n      <li>Oxaplat (TH);</li>\n      <li>Oxaplin (MY);</li>\n      <li>Oxerin (CO);</li>\n      <li>Oxitan (TH, ZW);</li>\n      <li>Oxitel (PH);</li>\n      <li>Oxol (LK, TH, ZW);</li>\n      <li>Planitox (VN);</li>\n      <li>Platinox (PH);</li>\n      <li>Pleoxtin (KR);</li>\n      <li>Plusplatin (EC);</li>\n      <li>Ranxor (SG);</li>\n      <li>Rexta (ID);</li>\n      <li>Rezykol (UA);</li>\n      <li>Riptam (MX);</li>\n      <li>Sanroxa (ID);</li>\n      <li>Sindoxplatin (PH);</li>\n      <li>Sinoxal (HR);</li>\n      <li>Vizoksal (UA);</li>\n      <li>X-Plat (LK);</li>\n      <li>Xaliplat (PY);</li>\n      <li>Xaloplat (BD);</li>\n      <li>Zildox (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18669868\"></a>Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Patients With Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction: A Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie. <i>Ann Oncol</i>. 2008;19(11):1882-1887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18669868/pubmed\" target=\"_blank\" id=\"18669868\">18669868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andre P, Cisternino S, Roy AL, et al, &ldquo;Stability of Oxaliplatin in Infusion Bags Containing 5% Dextrose Injection,&rdquo; <i>Am J Health Syst Pharm</i>, 2007, 64(18):1950-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17823107/pubmed\" target=\"_blank\" id=\"17823107\">17823107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15175436\"></a>Andre T, Boni C, Mounedji-Boudiaf L, et al, &ldquo;Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer,&rdquo; <i>N Engl J Med</i>, 2004, 350(23):2343-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/15175436/pubmed\" target=\"_blank\" id=\"15175436\">15175436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andre T, Boni C, Navarro M, et al, &ldquo;Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial,&rdquo; <i>J Clin Oncol</i>, 2009, 27(19):3109-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19451431/pubmed\" target=\"_blank\" id=\"19451431\">19451431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andre T, Tournigand C, Rosmorduc O, et al, &ldquo;Gemcitabine Combined With Oxaliplatin (GEMOX) in Advanced Biliary Tract Adenocarcinoma: A GERCOR Study,&rdquo; <i>Ann Oncol</i>, 2004, 15(9):1339-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/15319238/pubmed\" target=\"_blank\" id=\"15319238\">15319238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22226517\"></a>Bang YJ, Kim YW, Yang HK, et al, &ldquo;Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer After D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2012, 379(9813):315-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/22226517/pubmed\" target=\"_blank\" id=\"22226517\">22226517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16937105\"></a>Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours. <i>Cancer Chemother Pharmacol</i>. 2007;59(5):637-642.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/16937105/pubmed\" target=\"_blank\" id=\"16937105\">16937105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beaty O 3rd, Berg S, Blaney S, et.al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a children&rsquo;s oncology group study. <i>Pediatr Blood Cancer</i>. 2010;55:440-445.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20658614 /pubmed\" target=\"_blank\" id=\"20658614 \">20658614 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al, &ldquo;Biweekly Intensified Ambulatory Chronomodulated Chemotherapy With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Metastatic Colorectal Cancer,&rdquo; <i>J Clin Oncol</i>, 1996, 14(11):2950-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/8918492/pubmed\" target=\"_blank\" id=\"8918492\">8918492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhargava P, Gammon D, and McCormick MJ, &ldquo;Hypersensitivity and Idiosyncratic Reactions to Oxaliplatin,&rdquo; <i>Cancer</i>, 2004, 100(1):211-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14692042/pubmed\" target=\"_blank\" id=\"14692042\">14692042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18006893\"></a>Bokemeyer C, Oechsle K, Honecker F, et al, &ldquo;Combination Chemotherapy With Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Cisplatin-Refractory or Multiply Relapsed Germ-Cell Tumors: A Study of the German Testicular Cancer Study Group,&rdquo; <i>Ann Oncol</i>, 2008, 19(3):448-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18006893/pubmed\" target=\"_blank\" id=\"18006893\">18006893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brandi G, Pantaleo MA, Galli C, et al, &ldquo;Hypersensitivity Reactions Related to Oxaliplatin (OHP),&rdquo; <i>Br J Cancer</i>, 2003, 89(3):477-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12888815/pubmed\" target=\"_blank\" id=\"12888815\">12888815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cassidy J and Misset JL, &ldquo;Oxaliplatin-Related Side Effects: Characteristics and Management,&rdquo; <i>Semin Oncol</i>, 2002, 29(5 Suppl 15):11-20.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cassidy J, Clarke S, D&iacute;az-Rubio E, et al, &ldquo;Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin as First-Line Therapy for Metastatic Colorectal Cancer,&rdquo; <i>J Clin Oncol</i>, 2008, 26(12):2006-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18421053/pubmed\" target=\"_blank\" id=\"18421053\">18421053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cersosimo RJ, &ldquo;Oxaliplatin-Associated Neuropathy: A Review,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(1):128-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/15590869 /pubmed\" target=\"_blank\" id=\"15590869 \">15590869 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. <i>Ann Surg Oncol</i>. 2016;23(7):2315-2322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/26920385/pubmed\" target=\"_blank\" id=\"26920385\">26920385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21561347\"></a>Conroy T, Desseigne F, Ychou M, et al, &ldquo;FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer,&rdquo; <i>N Engl J Med</i>, 2011, 364(19):1817-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21561347/pubmed\" target=\"_blank\" id=\"21561347\">21561347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20940718\"></a>Conroy T, Yatagh&egrave;ne Y, Etienne PL, et al, &quot;Phase II Randomised Trial of Chemoradiotherapy With FOLFOX4 or Cisplatin Plus Fluorouracil in Oesophageal Cancer,&rdquo; <i>Br J Cancer</i>, 2010, 103(9):1349-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20940718/pubmed\" target=\"_blank\" id=\"20940718\">20940718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18172173\"></a>Cunningham D, Starling N, Rao S, et al, &ldquo;Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer,&rdquo; <i>N Engl J Med</i>, 2008, 358(1):36-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18172173/pubmed\" target=\"_blank\" id=\"18172173\">18172173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16757095\"></a>De Giorgi U, Rosti G, Aieta M, et al, &quot;Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients With Cisplatin-Refractory Nonseminomatous Germ Cell Tumor,&quot; <i>Eur Urol</i>, 2006, 50(5):1032-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/16757095/pubmed\" target=\"_blank\" id=\"16757095\">16757095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lemos ML and Walisser S, &ldquo;Management of Extravasation of Oxaliplatin,&rdquo;<i>J Oncol Pharm Pract</i>, 2005, 11(4):159-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/16595069/pubmed\" target=\"_blank\" id=\"16595069\">16595069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11886003\"></a>Dieras V, Bougnoux P, Petit T, et al, &ldquo;Multicentre Phase II Study of Oxaliplatin as a Single-Agent in Cisplatin/Carboplatin +/- Taxane-Pretreated Ovarian Cancer Patients,&rdquo; <i>Ann Oncol</i>, 2002, 13(2):258-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/11886003/pubmed\" target=\"_blank\" id=\"11886003\">11886003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doroshow JH, Synold TW, Gandara D, et al, &ldquo;Pharmacology of Oxaliplatin in Solid Tumor Patients With Hepatic Dysfunction: A Preliminary Report of the National Cancer Institute Organ Dysfunction Working Group,&rdquo; <i>Semin Oncol</i>, 2003, 30(4 Suppl 15):14-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14523790/pubmed\" target=\"_blank\" id=\"14523790\">14523790</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durand JP, Deplanque G, Montheil V, et al, &ldquo;Efficacy of Venlafaxine for the Prevention and Relief of Oxaliplatin-Induced Acute Neurotoxicity: Results of EFFOX, a Randomized, Double-Blind, Placebo-Controlled Phase III Trial,&rdquo; <i>Ann Oncol</i>, 2012, 23(1):200-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21427067/pubmed\" target=\"_blank\" id=\"21427067\">21427067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eloxatin (oxaliplatin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eloxatin (oxaliplating) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falcone A, Ricci S, Brunetti I, et al, &ldquo;Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest,&rdquo; <i>J Clin Oncol</i>, 2007, 25(13):1670-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17470860 /pubmed\" target=\"_blank\" id=\"17470860 \">17470860 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham MA, Lockwood GF, Greenslade D, et al, &ldquo;Clinical Pharmacokinetics of Oxaliplatin: A Critical Review,&rdquo; <i>Clin Cancer Res</i>, 2000, 6(4):1205-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10778943/pubmed\" target=\"_blank\" id=\"10778943\">10778943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grothey A, Nikcevich DA, Sloan JA, et al, &ldquo;Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7,&rdquo; <i>J Clin Oncol</i>, 2011, 29(4):421-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21189381/pubmed\" target=\"_blank\" id=\"21189381\">21189381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20209610\"></a>Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. <i>Cancer</i>. 2010;116(10):2448-2454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20209610/pubmed\" target=\"_blank\" id=\"20209610\">20209610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haller DG, Tabernero J, Maroun J, et al, &ldquo;Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid as Adjuvant Therapy for Stage III Colon Cancer,&rdquo; <i>J Clin Oncol</i>, 2011, 29(11):1465-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21383294/pubmed\" target=\"_blank\" id=\"21383294\">21383294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo; <i>Ann Oncol</i>, 2010, 21(7):1395-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khushalani NI, Leichman CG, Proulx G, et al, &ldquo;Oxaliplatin in Combination with Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal Cancer,&rdquo; <i>J Clin Oncol</i>, 2002, 20(12):2844-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12065561/pubmed\" target=\"_blank\" id=\"12065561\">12065561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim BH, Bradley T, Tai J, et al, &ldquo;Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review,&rdquo; <i>Oncology</i>, 2009, 76(4):231-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19246947/pubmed\" target=\"_blank\" id=\"19246947\">19246947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Knijn N, Tol J, Koopman M, et al, &ldquo;The Effect of Prophylactic Calcium and Magnesium Infusions on the Incidence of Neurotoxicity and Clinical Outcome of Oxaliplatin-Based Systemic Treatment in Advanced Colorectal Cancer Patients,&rdquo; <i>Eur J Cancer</i>, 2011, 47(3):369-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21067912/pubmed\" target=\"_blank\" id=\"21067912\">21067912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14701772\"></a>Kollmannsberger C, Beyer J, Liersch R, et al, &ldquo;Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group,&rdquo; <i>J Clin Oncol</i>, 2004, 22(1):108-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14701772/pubmed\" target=\"_blank\" id=\"14701772\">14701772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KueblerJP, Wieand HS, O'Connell MJ, et al, &ldquo;Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin as Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07,&rdquo; <i>J Clin Oncol</i>, 2007, 25(16):2198-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17470851/pubmed\" target=\"_blank\" id=\"17470851\">17470851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levi F, Metzger G, Massari C, et al, &ldquo;Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects,&rdquo; <i>Clin Pharmacokinet</i>, 2000, 38(1):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10668856/pubmed\" target=\"_blank\" id=\"10668856\">10668856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levi M, Shalgi R, Brenner B, et al. The impact of oxaliplatin on the gonads: from bedside to the bench. <i>Mol Hum Reprod</i>. 2015;21(12):885-893. doi:10.1093/molehr/gav055.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/26443807/pubmed\" target=\"_blank\" id=\"26443807\">26443807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18005385\"></a>L&oacute;pez A, Guti&eacute;rrez A, Palacios A, et al, &ldquo;GEMOX-R Regimen is a Highly Effective Salvage Regimen in Patients With Refractory/Relapsing Diffuse Large-Cell Lymphoma: A Phase II Study,&rdquo; <i>Eur J Haematol</i>, 2008, 80(2):127-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18005385/pubmed\" target=\"_blank\" id=\"18005385\">18005385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loprinzi CL, Qin R, Dakhil SR, et al, &ldquo;Phase III Randomized, Placebo (PL)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: An Alliance for Clinical Trials in Oncology Study,&rdquo; <i>J Clin Oncol</i>, 2013, 31 (suppl): 3501 [abstract 3501 from 2013 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23335436\"></a>Mascarenhas L, Malogolowkin M, Armenian SH, Sposto R, Venkatramani R. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic soldi tumors. <i>Pediatric Blood Cancer</i>. 2013;60:1103-1107. doi: 10.1002/pbc.24471.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/23335436/pubmed\" target=\"_blank\" id=\"23335436\">23335436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18182984\"></a>Nehls O, Oettle H, Hartmann JT, et al, &ldquo;Capecitabine Plus Oxaliplatin as First-Line Treatment in Patients With Advanced Biliary System Adenocarcinoma: A Prospective Multicentre Phase II Trial,&rdquo; <i>Br J Cancer</i>, 2008, 98(2):309-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18182984/pubmed\" target=\"_blank\" id=\"18182984\">18182984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oechsle K, Kollmannsberger C, Honecker F, et al, &ldquo;Long-Term Survival After Treatment With Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients With Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors,&rdquo; <i>Eur Urol</i>, 2011, 60(4):850-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21704446/pubmed\" target=\"_blank\" id=\"21704446\">21704446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Neill MT, Ni Dhonnchu T, Brannigan AE. Topic update: effects of colorectal cancer treatments on female fertility and potential methods for fertility preservation. <i>Dis Colon Rectum</i>. 2011;54(3):363-369. doi:10.1007/DCR.0b013e31820240b3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24901360/pubmed\" target=\"_blank\" id=\"24901360\">24901360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&#700;Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. <i>Ann Surg</i>. 2014;260(1):142-148.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24901360/pubmed\" target=\"_blank\" id=\"24901360\">24901360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oxaliplatin [prescribing information]. Pine Brook, PA: Alvogen Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14998855\"></a>Pectasides D, Pectasides M, Farmakis D, et al, &ldquo;Gemcitabine and Oxaliplatin (GEMOX) in Patients With Cisplatin-Refractory Germ Cell Tumors: A Phase II Study,&rdquo; <i>Ann Oncol</i>, 2004, 15(3):493-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14998855/pubmed\" target=\"_blank\" id=\"14998855\">14998855</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10715288\"></a>Piccart MJ, Green JA, Lacave AJ, et al, &ldquo;Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group,&rdquo; <i>J Clin Oncol</i>, 2000, 18(6):1193-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10715288/pubmed\" target=\"_blank\" id=\"10715288\">10715288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polyzos A, Tsavaris N, Gogas H, et al, &ldquo;Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience,&rdquo; <i>Oncology</i>, 2009, 76(1):36-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19033714/pubmed\" target=\"_blank\" id=\"19033714\">19033714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramanathan PK, Rothenberg ML, de Gramont A, et al, &ldquo;Incidence and Evolution of Oxaliplatin-Induced Peripheral Sensory Neuropathy in Diabetic Patients With Colorectal Cancer: A Pooled Analysis of Three Phase III Studies,&rdquo; <i>Ann Oncol</i>, 2010, 21(4):754-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19887466/pubmed\" target=\"_blank\" id=\"19887466\">19887466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17990179\"></a>Rodr&iacute;guez J, Gutierrez A, Palacios A, et al, &ldquo;Rituximab, Gemcitabine and Oxaliplatin: An Effective Regimen in Patients With Refractory and Relapsing Mantle Cell Lymphoma,&rdquo; <i>Leuk Lymphoma</i>, 2007, 48(11):2172-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17990179/pubmed\" target=\"_blank\" id=\"17990179\">17990179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saltz LB, Clarke S, D&iacute;az-Rubio E, et al, &ldquo;Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,&rdquo; <i>J Clin Oncol</i>, 2008, 26(12):2013-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18421054/pubmed\" target=\"_blank\" id=\"18421054\">18421054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shi Q, Sobrero AF, Shields AF, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. <i>J Clin Oncol</i>. 2017;35(suppl): LBA1 [Abstract LBA1 from 2017 ASCO annual meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suenaga M, Mizunuma N, Shinozaki E, et al, &ldquo;Management of Allergic Reactions to Oxaliplatin in Colorectal Cancer Patients,&rdquo; <i>J Support Oncol</i>, 2008, 6(8):373-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19149322/pubmed\" target=\"_blank\" id=\"19149322\">19149322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synold TW, Takimoto CH, Doroshow JH, et al, &ldquo;Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients With Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study,&rdquo; <i>Clin Cancer Res</i>, 2007, 13(12):3660-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17575231/pubmed\" target=\"_blank\" id=\"17575231\">17575231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takimoto CH, Graham MA, Lockwood G, et al, &ldquo;Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer patients With Impaired Renal Function,&rdquo; <i>Clin Cancer Res</i>, 2007, 13(16):4832-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17699862/pubmed\" target=\"_blank\" id=\"17699862\">17699862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takimoto CH, Remick SC, Sharma S, et al, &ldquo;Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study,&rdquo; <i>J Clin Oncol</i>, 2003, 21(14):2664-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12860942/pubmed\" target=\"_blank\" id=\"12860942\">12860942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25551355\"></a>Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L.Oxaliplatin and doxorubicin for relapsed or refractory high-risk neuroblastoma. <i>Pediatr Hematol Oncol</i>. 2015;32(1):26-31. doi: 10.3109/08880018.2014.983624.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/25551355/pubmed\" target=\"_blank\" id=\"25551355\">25551355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA, Saenz CA, Ingram DS, et al, &ldquo;Compatibility Screening of Oxaliplatin During Simulated Y-Site Administration With Other Drugs,&rdquo; <i>J Oncol Pharm Practice</i>, 2002, 8(1):33-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18182662\"></a>Tsimberidou AM, Wierda WG, Plunkett W, et al, &ldquo;Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2008, 26(2):196-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18182662/pubmed\" target=\"_blank\" id=\"18182662\">18182662</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang Y, Yu YY, Li W, et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. <i>Cancer Chemother Pharmacol</i>. 2014;73(6):1155-1161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24748418/pubmed\" target=\"_blank\" id=\"24748418\">24748418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiseman LR, Adkins JC, Plosker GL, et al, &ldquo;Oxaliplatin: A Review of Its Use in the Management of Metastatic Colorectal Cancer,&rdquo; <i>Drugs Aging</i>, 1999, 14(6):459-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10408744/pubmed\" target=\"_blank\" id=\"10408744\">10408744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18756532\"></a>Xiong HQ, Varadhachary GR, Blais JC, et al, &ldquo;Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-Line Therapy for Patients With Advanced Pancreatic Cancer,&rdquo; <i>Cancer</i>, 2008, 113(8):2046-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18756532/pubmed\" target=\"_blank\" id=\"18756532\">18756532</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10180 Version 199.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709183\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204261\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6821523\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F204285\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F204263\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F50906907\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F204264\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F204265\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F6821524\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20342799\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F204286\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204242\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F204229\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F204244\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132766\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F204243\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469518\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F204295\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204234\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204247\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204232\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299798\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204236\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204238\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204249\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3017308\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F204240\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204231\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F204246\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323568\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539908\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10180|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxaliplatin-patient-drug-information\" class=\"drug drug_patient\">Oxaliplatin: Patient drug information</a></li><li><a href=\"topic.htm?path=oxaliplatin-pediatric-drug-information\" class=\"drug drug_pediatric\">Oxaliplatin: Pediatric drug information</a></li></ul></div></div>","javascript":null}